In order to prevent renal and cardiovascular outcomes in persons with type 2 diabetes and CKD who have not attained glycemic objectives, the American Diabetes Association supports the use of SGLT2 inhibitors along with metformin, which is also in accordance with the KDIGO 2022 draught recommendations [10]. The gene discussed is SLC5A2; the disease is chronic kidney disease.